Last reviewed · How we verify
"Standard" rFSH dose
Recombinant follicle-stimulating hormone (rFSH) stimulates the growth and maturation of ovarian follicles in women undergoing fertility treatment.
Recombinant follicle-stimulating hormone (rFSH) stimulates the growth and maturation of ovarian follicles in women undergoing fertility treatment. Used for Infertility in women undergoing assisted reproductive technology (ART) / in vitro fertilization (IVF), Anovulation and ovulatory dysfunction.
At a glance
| Generic name | "Standard" rFSH dose |
|---|---|
| Sponsor | Nina la Cour Freiesleben |
| Drug class | Gonadotropin |
| Target | FSH receptor (FSHR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
rFSH is a recombinant version of the naturally occurring pituitary hormone FSH that binds to FSH receptors on granulosa cells in the ovary, promoting follicle development and estrogen production. This controlled stimulation is used during assisted reproductive technology cycles to generate multiple mature oocytes for retrieval and fertilization.
Approved indications
- Ovulation induction in women with anovulation or oligo-ovulation
- Controlled ovarian hyperstimulation in assisted reproductive technology (ART) cycles
- In vitro fertilization (IVF)
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/bloating
- Nausea
- Ovarian cysts
Key clinical trials
- hCG Priming in Women With Diminished Ovarian Reserve (PHASE3)
- C677T Methylenetetrahydrofolate Reductase Mutation
- hCG Priming in Women With Low Ovarian Reserve (PHASE4)
- Low-dose HCG as an Adjunct to Ovarian Stimulation in Subfertile Women Undergoing ART (PHASE3)
- Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study
- Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles (PHASE4)
- Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity (NA)
- Pretreatment With Estradiol Valerate (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- "Standard" rFSH dose CI brief — competitive landscape report
- "Standard" rFSH dose updates RSS · CI watch RSS
- Nina la Cour Freiesleben portfolio CI